cAd3-EBO Z: Phase I started

Bavarian Nordic A/S (CSE:BAVA, Kvistgaard, Denmark) said the University of Oxford began an open-label, dose-escalation, U.K. Phase I trial to evaluate 2 doses of the company’s MVA-BN Filo and 3 doses of intramuscular cAd3-EBO Z from GlaxoSmithKline in about 60 volunteers ages 18-50. Subjects will receive cAd3-EBO Z alone or with a booster dose of MVA-BN Filo. ...